Why 5.

In the single-arm phase 2 2SMART trial, 30 men with low (7%) or intermediate (93%) risk prostate cancer were treated with 2-fraction SBRT. The targets included the dominant intraprostatic nodule and the prostate CTV with a 2-3 mm margin. The prostate was prescribed 26 Gy in 2 fractions while the nodule received a 32 Gy simultaneous integrated boost. Median PSA nadir was 0.25 at a median 37 months. One patient (3%) had a biochemical failure. There was no grade 3 toxicity. The rates of minimally clinically important change in urinary, bowel, and sexual QOL domains were 33%, 20%, and 10%. | Ong, Radiother Oncol 2023